Lincoln Pharma Reports 17% Net Profit Growth in Q1, Targets ₹1,000 Crore Revenue in 3 Years
Lincoln Pharmaceuticals reported strong Q1 FY26 results with a 17% increase in net profit to ₹27.70 crore and a 7.3% rise in total income to ₹169.34 crore. EBITDA grew by 17.92% to ₹39.08 crore. The company aims to achieve ₹1,000 crore in revenue within three years, targeting 15-18% annual growth. Lincoln Pharma launched a bulk drug manufacturing plant and received approvals for 10 products. The company's shares closed at ₹576.90 on BSE, up 8.47%.
07Aug 25
Lincoln Pharmaceuticals Reports 16.93% Profit Growth in Q1, Reappoints Key Directors
Lincoln Pharmaceuticals reported a 16.93% year-on-year increase in Q1 net profit to Rs. 27.70 crore. Total income rose by 7.39% to Rs. 169.34 crore, while EBITDA grew 17.92% to Rs. 39.08 crore. The company re-appointed key leadership positions, including Mahendra G. Patel as Managing Director. Lincoln aims to achieve Rs. 1,000 crore revenue within three years, targeting 15-18% annual growth. The company plans to expand its global presence from 60+ to 90 countries in 2-3 years. FII stake in the company increased from 3.95% to 5.13% over the past year.
02Jul 25
Lincoln Pharmaceuticals Completes Trial Run at Khatraj Facility, Eyes API Production
Lincoln Pharmaceuticals has successfully completed the trial run of its Khatraj facility, a key step in its expansion plans. The company aims to commence commercial production of Active Pharmaceutical Ingredients (APIs) at this facility within 1-2 years, subject to regulatory approvals. This move is expected to enhance manufacturing capabilities, potentially leading to vertical integration, cost efficiency, improved quality control, and stronger market positioning.